Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91–113.

Article  CAS  PubMed  Google Scholar 

Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lehmann BD, Jovanović B, Chen XI, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE. 2016. https://doi.org/10.1371/journal.pone.0157368.

Article  PubMed  PubMed Central  Google Scholar 

Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18(2):123–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–98.

Article  CAS  PubMed  Google Scholar 

Jiang YZ, Ma D, Suo C, et al. Genomic and Transcriptomic Landscape of Triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3):428–440e5.

Article  CAS  PubMed  Google Scholar 

Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor [published correction appears in Cancer J. 2010 Nov-Dec;16(6):643]. Cancer J. 2010;16(1):62–65.

Gerratana L, Basile D, Buono G, et al. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev. 2018;68:102–10.

Article  CAS  PubMed  Google Scholar 

Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast Cancer. Clin Cancer Res. 2013;19(19):5505–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonnefoi H, Grellety T, Tredan O, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12 – 1). Ann Oncol. 2016;27(5):812–8.

Article  CAS  PubMed  Google Scholar 

Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the treatment of androgen receptor-expressing Triple-negative breast Cancer. J Clin Oncol. 2018;36(9):884–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Astvatsaturyan K, Yue Y, Walts AE, Bose S. Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features. PLoS ONE. 2018. https://doi.org/10.1371/journal.pone.0197827.

Article  PubMed  PubMed Central  Google Scholar 

Pistelli M, Caramanti M, Biscotti T, et al. Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. Cancers (Basel). 2014;6(3):1351–62.

Article  PubMed  Google Scholar 

Qu Q, Mao Y, Fei XC, Shen KW. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS ONE. 2013. https://doi.org/10.1371/journal.pone.0082650.

Article  PubMed  PubMed Central  Google Scholar 

Wang C, Pan B, Zhu H, et al. Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget. 2016;7(29):46482–91.

Article  PubMed  PubMed Central  Google Scholar 

Kim Y, Jae E, Yoon M. Influence of androgen receptor expression on the survival outcomes in breast Cancer: a Meta-analysis. J Breast Cancer. 2015;18(2):134–42.

Article  PubMed  PubMed Central  Google Scholar 

Asano Y, Kashiwagi S, Goto W, et al. Expression and clinical significance of androgen receptor in Triple-negative breast Cancer. Cancers (Basel). 2017. https://doi.org/10.3390/cancers9010004.

Article  PubMed  Google Scholar 

Bi J, Wu Z, Zhang X, et al. TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression. Nat Commun. 2023. https://doi.org/10.1038/s41467-023-38115-2.

Article  PubMed  PubMed Central  Google Scholar 

Lehmann BD, Bauer JA, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014. https://doi.org/10.1186/s13058-014-0406-x.

Article  PubMed  PubMed Central  Google Scholar 

Coussy F, Lavigne M, de Koning L, et al. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Theranostics. 2020;10(4):1531–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Juric D, Janku F, Rodón J, et al. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-type estrogen receptor-positive advanced breast Cancer: a phase 1b clinical trial. JAMA Oncol. 2019. https://doi.org/10.1001/jamaoncol.2018.4475.

Article  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105–22.

Article  CAS  PubMed  Google Scholar 

Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158–65.

Article  CAS  PubMed  Google Scholar 

Xin L, Wu Q, Zhan C, et al. Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese society of breast surgery 021). Chin Med J (Engl). 2022;135(6):697–706.

Article  CAS  PubMed  Google Scholar 

Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3(2):224–37.

Article  CAS  PubMed  Google Scholar 

Zuo WJ, Jiang YZ, Wang YJ, et al. Dual characteristics of Novel HER2 kinase domain mutations in response to HER2-Targeted therapies in human breast Cancer. Clin Cancer Res. 2016;22(19):4859–69.

Article  CAS  PubMed  Google Scholar 

O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417–30.

Article  PubMed  Google Scholar 

Cai Z, Wang J, Li Y, et al. Overexpressed cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. Sci China Life Sci. 2023;66(1):94–109.

Article  CAS  PubMed  Google Scholar 

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.

Article  Google Scholar 

Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dvinge H, Git A, Gräf S, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497(7449):378–82.

Article  CAS  PubMed  Google Scholar 

Mulrane L, McGee SF, Gallagher WM, O’Connor DP. miRNA dysregulation in breast cancer. Cancer Res. 2013;73(22):6554–62.

Article  CAS  PubMed  Google Scholar 

Shi Y, Yang F, Sun Z, Zhang W, Gu J, Guan X. Differential microRNA expression is associated with androgen receptor expression in breast cancer. Mol Med Rep. 2017;15(1):29–36.

Article  CAS  PubMed  Google Scholar 

Angelova M, Charoentong P, Hackl H, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015. https://doi.org/10.1186/s13059-015-0620-6.

Article  PubMed  PubMed Central  Google Scholar 

O’Meara T, Safonov A, Casadevall D, et al. Immune microenvironment of triple-negative breast cancer in African-American and caucasian women. Breast Cancer Res Treat. 2019;175(1):247–59.

Article  PubMed  PubMed Central  Google Scholar 

Goff SL, Danforth DN. The role of Immune cells in breast tissue and immunotherapy for the treatment of breast Cancer. Clin Breast Cancer. 2021. https://doi.org/10.1016/j.clbc.2020.06.011.

Article  PubMed